Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Glaukos ( (GKOS) ).
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology specialist in glaucoma, corneal and retinal therapies, reported strong first-quarter 2026 performance on April 29, 2026, driven by its micro-invasive glaucoma devices and newer products such as the iDose TR long-duration intracameral therapy. The company, which also markets the only FDA-approved corneal cross-linking therapy for keratoconus, continues to build out a pipeline of dropless, sustained-delivery platform technologies aimed at improving outcomes for patients with chronic eye disease.
For the quarter ended March 31, 2026, Glaukos posted record net sales of $150.6 million, up 41% year-on-year, with glaucoma revenue climbing 47% to $129.3 million and U.S. glaucoma sales jumping 58% to $93.5 million. Gross margin improved to about 78% on a GAAP basis and 84% on a non-GAAP basis, and although the company remained loss-making, operating and net losses narrowed on a non-GAAP basis, while Glaukos closed the period with roughly $280.5 million in cash and no debt.
Management highlighted robust global execution and momentum from two key growth drivers, iDose TR and Epioxa, and raised full-year 2026 net sales guidance to a range of $620 million to $635 million from the prior $600 million to $620 million. The company also published a “Quarterly Summary” on its investor relations site to streamline communications with the investment community, underscoring its effort to increase transparency as it invests heavily in R&D and commercial capabilities to support long-term growth in ophthalmic therapeutics.
The most recent analyst rating on (GKOS) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
The score is driven mainly by weak fundamentals (losses, margin compression, and negative cash flow) despite strong revenue growth and improving leverage. Technicals are supportive with the stock in a clear uptrend, and the latest earnings call reinforced a positive growth outlook for 2026, but valuation remains constrained by ongoing unprofitability.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops and commercializes novel therapies for glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS), launched its first MIGS device in 2012, and has since expanded into long-duration intracameral glaucoma drugs such as iDose TR and FDA-approved corneal cross-linking therapies for keratoconus, targeting patients with chronic eye diseases worldwide.
Headquartered in Aliso Viejo, Calif., Glaukos focuses on dropless platform technologies intended to improve standards of care and clinical outcomes across ophthalmology. Its portfolio spans implantable drug-delivery systems and bio-activated pharmaceuticals, positioning the company at the intersection of device and drug innovation in a growing global market for minimally invasive and sustained eye-disease treatments.
Average Trading Volume: 706,800
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.14B
See more data about GKOS stock on TipRanks’ Stock Analysis page.